Fate Therapeutics (FATE) vs Lexeo Therapeutics (LXEO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Fate Therapeutics (FATE) has outperformed Lexeo Therapeutics (LXEO) over the past year, gaining 54.7% versus a loss of 60.3%. Lexeo Therapeutics is the larger company by market cap ($271.7 million vs $257.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FATE | LXEO |
|---|---|---|
| Share price | $2.15 | $3.31 |
| Market cap | $257.61M | $271.71M |
| 1-day change | -6.11% | +0.30% |
| YTD return | +119.39% | -66.67% |
| 1-year return | +54.68% | -60.31% |
| 5-year return | -96.49% | — |
| EPS (TTM) | $-0.99 | $-1.02 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.23 | $10.99 |
| 52-week low | $0.95 | $2.98 |
| Distance from 52-week high | -33.44% | -69.88% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +166.98% | +513.29% |
| Average volume | 1.90M | 1.17M |
| Shares outstanding | 119.82M | 82.09M |
| Employees | 161 | 63 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- FATE has outperformed LXEO by 115.0 percentage points over the past year.
About Fate Therapeutics
FATE stock →Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity.
Healthcare · Biotechnology · 161 employees
About Lexeo Therapeutics
LXEO stock →Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy.
Healthcare · Biotechnology · 63 employees
FATE vs LXEO FAQ
Which is bigger, Fate Therapeutics or Lexeo Therapeutics?
Lexeo Therapeutics (LXEO) is larger, with a market capitalization of $271.71M compared with $257.61M for Fate Therapeutics (FATE).
Which stock has performed better over the past year, FATE or LXEO?
FATE returned +54.68% over the past 12 months, compared with -60.31% for LXEO (price return, excluding dividends). Past performance does not predict future results.
Are Fate Therapeutics and Lexeo Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.